

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

上海復星醫藥（集團）有限公司
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02196)

2020 HIRD Q₃ AR ERL REPOR

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report for 2020 of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “Company”, together with its subsidiaries, collectively the “Group”) (the “2020 Q₃ Report”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.

By Order of the Board

上海復星醫藥（集團）有限公司
Chairman

Shanghai, the People's Republic of China

29 October 2020

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* for identification purposes only

1. IMPOR AN NO ICE

- 1.1 The board of directors (the “**B**”) and the supervisory committee (the “**C**”) of the Company and its directors, supervisors and senior management warrant that the 2020 Third Quarterly Report of the Group does not contain any false information, misleading statements or material omission and severally and jointly accept legal responsibility for the truthfulness, accuracy and completeness of the contents contained herein.
- 1.2 All directors of the Company attended the Board meeting to review the 2020 Third Quarterly Report of the Group.
- 1.3 Chen Qiyu, the person in charge of the Company, Guan Xiaohui, the Chief Financial Officer, and Chen Zhanyu, the Director of the Accounting Department (Accounting Officer) duly declare that they warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2020 Third Quarterly Report of the Group.
- 1.4 The 2020 Third Quarterly Report of the Group has not been audited.

2. MAJOR FINANCIAL INFORMATION AND CHANGE IN SHAREHOLDER OF THE GROUP

2.1 Major financial information

Unit: Yuan Currency: RMB

	30 Dec 2020	31 Dec 2019	Change (%)
Total assets	80,547,989,215.24	76,119,645,663.32	5.82
Net assets attributable to shareholders of the listed company	33,083,709,544.28	31,888,066,063.03	3.75
	J 6 - 2020	J 6 - 2019	Change (%)
Net cash flow generated from operating activities	2,453,135,520.00	2,328,355,784.17	5.36
	J 6 - 2020	J 6 - 2019	Change (%)
Operating revenue	22,102,744,284.03	21,227,618,679.11	4.12
Net profit attributable to shareholders of the listed company	2,478,980,552.00	2,063,704,147.99	20.12
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss	2,059,539,441.46	1,722,388,028.34	19.57
Weighted average return on net assets (%)	7.52	7.21	Increase by 0.31 percentage point
Basic earnings per share (RMB/share)	0.97	0.81	19.75
Diluted earnings per share (RMB/share)	0.97	0.81	19.75

Extraordinary gain or loss items and amounts

Unit: Yuan Currency: RMB

Item	J - 2020	J 6 - 2020
Gain or loss on disposal of non-current assets	59,844,008.57	148,673,855.03
Government grant included in profit or loss for the current period (excluding government grant closely related to the Company's normal operation, and entitled in fixed amounts or quantities on a continuous basis according to national standards)	6,590,725.79	63,073,671.90
Profit or loss arising from changes in the fair value of holding held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities, and investment income from disposal of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities, derivative financial liabilities and other debt investments, except effective hedging business related to the Company's normal operations	-21,836,656.22	418,849,091.49
Non-operating income and expenses other than those stated above	-	

2.2 Total number of shareholders, the shareholding status of the Top 10 shareholders and the Top 10 tradable shareholders (or unrestricted shareholders) of the Company at the end of the Reporting Period

Unit: Share

Total number of shareholders				324,777		
Name of Shareholder	Number of Shares	Percentage (%)	Number of Tradable Shares	Shareholding Status		Type of Shareholder
				None	Number of Shares	
SHANGHAI FOSUN HIGH TECHNOLOGY (GROUP) COMPANY LIMITED*	938,095,290	36.60	0	None	0	Domestic non-state owned legal entity
HKSCC NOMINEES LIMITED (Note 1)	551,060,098	21.50	0	Unknown	—	Unknown
CHINA SECURITIES FINANCE CORPORATION LIMITED	38,736,157	1.51	0	None	0	State owned legal entity
HONG KONG SECURITIES CLEARING COMPANY LIMITED (Note 2)	33,849,388	1.32	0	None	0	Unknown
CHINA LIFE INSURANCE COMPANY LIMITED — TRADITIONAL — ORDINARY INSURANCE PRODUCT — 005L — CT001 SHANGHAI*	26,772,761	1.04	0	None	0	Others
CENTRAL HUIJIN ASSET MANAGEMENT LTD.*	24,067,700	0.94	0	None	0	State owned legal entity
ABU DHABI INVESTMENT AUTHORITY	18,510,795	0.72	0	None	0	Overseas legal entity
TAIKANG LIFE INSURANCE CO., LTD. — DIVIDEND — INDIVIDUAL DIVIDEND — 019L — FH002 SHANGHAI*	10,569,000	0.41	0	None	0	Others
CENTRAL BANK OF MALAYSIA	8,766,765	0.34	0	None	0	Unknown
INDUSTRIAL AND COMMERCIAL BANK OF CHINA — SSE 50 TRADED OPEN-END INDEX SECURITIES INVESTMENT FUND*	8,717,381	0.34	0	None	0	Others

10			
N	N	6	N
6	6	6	6
6	6	6	6
SHANGHAI FOSUN HIGH TECHNOLOGY (GROUP) COMPANY LIMITED*	938,095,290	RMB ordinary shares	938,095,290
HKSCC NOMINEES LIMITED (Note 1)	551,060,098	Overseas listed foreign shares	551,060,098
CHINA SECURITIES FINANCE CORPORATION LIMITED	38,736,157	RMB ordinary shares	38,736,157
HONG KONG SECURITIES CLEARING COMPANY LIMITED (Note 2)	33,849,388	RMB ordinary shares	33,849,388
CHINA LIFE INSURANCE COMPANY LIMITED — TRADITIONAL — ORDINARY INSURANCE PRODUCT — 005L — CT001 SHANGHAI*	26,772,761	RMB ordinary shares	26,772,761
CENTRAL HUIJIN ASSET MANAGEMENT LTD.*	24,067,700	RMB ordinary shares	24,067,700
ABU DHABI INVESTMENT AUTHORITY	18,510,795	RMB ordinary shares	18,510,795
TAIKANG LIFE INSURANCE CO., LTD. — DIVIDEND — INDIVIDUAL DIVIDEND — 019L — FH002 SHANGHAI*	10,569,000	RMB ordinary shares	10,569,000
CENTRAL BANK OF MALAYSIA	8,766,765	RMB ordinary shares	8,766,765
INDUSTRIAL AND COMMERCIAL BANK OF CHINA — SSE 50 TRADED OPEN-END INDEX SECURITIES INVESTMENT FUND*	8,717,381	RMB ordinary shares	8,717,381
Description of the related relationship or concerted action of the above shareholders	The Company do.7(FU).1(he)-389.3(related)-389.5(r)1.5(relationship)-389.5(o)2.		

3. SIGNIFICANT EVENTS

3.1 Significant changes in major financial statement items and financial indicators of the Group and the reasons thereof

(1) Balance Sheet

Unit: Yuan Currency: RMB

	Balance Sheet			
Item	30 Dec 2020	31 Dec 2019	Ratio	Reasons
Financial assets held for trading	1,016,412,863.26	456,650,637.52	122.58%	Mainly due to the purchase of the shares of BioNTech SE during the Reporting Period
Prepayments	594,704,488.24	415,675,156.23	43.07%	Mainly due to the increase in prepayments for goods during the Reporting Period
Other equity instrument investments	16,208,856.24	107,709,225.73	-84.95%	Mainly due to the disposal of financial assets during the Reporting Period
Long-term deferred expenditures	269,914,243.62	160,688,247.32	67.97%	Mainly due to the increase in renovation projects of leased properties during the Reporting Period
Bills payable	355,538,961.44	244,567,689.32	45.37%	Mainly due to the increased payments by bills during the Reporting Period
Non-current liabilities due within one year	4,278,199,659.78	2,562,263,003.09	66.97%	Mainly due to (1) the reclassification of the RMB3 billion corporate bonds with repurchase option ("16 Fosun Pharma 01") expired on 4 March 2021 to "non-current liabilities due within one year" for accounting during the Reporting Period; (2) the transfer of part of the expired and renewed amount of the RMB1.25 billion corporate bonds with repurchase option ("17 Fosun Pharma 01") on 14 March 2020 from "non-current liabilities due within one year" to "bonds payable" for accounting during the Reporting Period
Other current liabilities	667,693,045.69	248,969,275.20	168.18%	Mainly due to the issuance of super short-term commercial papers by the Company during the Reporting Period
Bonds payable	3,386,675,610.44	5,283,863,183.83	-35.91%	Mainly due to the reclassification of the RMB3 billion corporate bonds with repurchase option ("16 Fosun Pharma 01") to "non-current liabilities due within one year" and the renewal of the RMB1.25 billion corporate bonds ("17 Fosun Pharma 01") during the Reporting Period

(2) Income Statement

Unit: Yuan Currency: RMB

	I 6 6			
I 6 6	J 6 - 2020	J 6 - 2019	R 6 6	R 6 6
Research and development expenses	1,877,700,493.10	1,290,028,940.00	45.55%	Mainly due to the increase in the research and development expenditure in biopharmaceutical drugs, small molecular innovative drugs and imported innovative drugs, and increased investment in innovation incubation platform during the Reporting Period
Credit impairment losses	-54,308,952.12	-28,035,808.23	93.71%	Mainly due to the provision for impairment loss on accounts receivable expected to be unrecoverable based on the credit impairment model
Other gains	241,785,580.17	177,190,761.04	36.45%	Mainly due to the increase in government grants during the Reporting Period
Gains from changes in fair value	3,424,448.30	-130,280,259.91	102.63%	Mainly due to the decline in the price of financial assets held in the same period of last year and the transfer of cumulative fair value changes corresponding to the disposal of financial assets to investment income
Gains from disposal of assets	1,840,134.37	18,274,543.61	-89.93%	Mainly due to the effect of disposal of fixed assets during the Reporting Period
Non-operating revenue	12,558,825.08	60,837,112.62	-79.36%	Mainly due to the effect of payments that are not required to be paid in the same period of last year
Profit or loss attributable to non-controlling interests	270,908,243.26	391,892,841.31	-30.87%	Mainly due to the acquisition of certain minority interests in Breas Medical Holdings AB, Sisram Medical Ltd., Tridem Pharma S.A.S, Suzhou Erye Pharmaceutical Co., Ltd.* and Chongqing Yao Pharmaceutical Co., Ltd.* and the changes in profit or loss in certain non-wholly-owned subsidiaries during the Reporting Period
Other comprehensive income, net of tax	-100,190,979.89	34,958,479.93	-386.60%	Mainly due to the foreign currency translation difference arising from fluctuations in foreign currency exchange rates

(3) Statement of Cash Flow

Unit: Yuan Currency: RMB

Items	2020		Change Ratio	Reasons
	Year-end	Year-end		
Net cash flow generated from investing activities	-3,584,386,012.17	-2,560,243,375.55	-40.00%	Mainly due to the period-on-period increase in funds paid for investment in fixed assets during the Reporting Period
Net cash flow generated from financing activities	-66,215,438.18	2,663,982,639.53	-102.49%	Mainly due to the receipt of proceeds by the controlling subsidiary Shanghai Henlius Biotech, Inc. in the same period of last year, and the repayment of loans during the Reporting Period
Effects of exchange rate fluctuations on cash and cash equivalents	-132,918,882.81	47,762,255.60	-378.29%	Mainly due to the exchange rate fluctuations during the Reporting Period

3.2 Analysis and explanation of the progress, impact and solution of major events

- On 30 December 2019, the 2019 third extraordinary general meeting of the Company considered and approved, among other matters, the spin-off of Gland Pharma Limited (“Gland Pharma”) and its overseas listing plan. The holding subsidiary Gland Pharma was proposed to be listed on the National Stock Exchange of India Limited and BSE Limited.

During the Reporting Period, Gland Pharma has filed the draft red herring prospectus with the Securities and Exchange Board of India, the National Stock Exchange of India Limited and BSE Limited, in relation to its proposed initial public offering of its shares. As at the end of the Reporting Period, the Company has received the “Letter Regarding the Spin-off and Overseas Listing of Subsidiary by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Guo He Han [2020] No. 417)” from the International Cooperation Division of China Securities Regulatory Commission (“CSRC”), pursuant to which, the International Cooperation Division of CSRC has no objection to relevant matters regarding the spin-off and overseas listing of Gland Pharma. The Stock Exchange of Hong Kong Limited has confirmed that the Company may proceed with the spin-off and overseas listing of Gland Pharma. Gland Pharma has received the in-principle approval for the listing on the National Stock Exchange of India Limited and BSE Limited.

As at the end of the Reporting Period, the overseas listing of Gland Pharma is subject to, among other things, the approval of the relevant regulatory authorities in India.

2. Fosun High Tech (and/or by parties acting in concert with it) intended to further increase its shareholding in the Company (including A shares and/or H shares) via the trading system of the Shanghai Stock Exchange (including the Shanghai-Hong Kong Stock Connect) from 19 September 2019 to 18 September 2020, if and where appropriate, and the cumulative total amount thereof shall not be less than RMB100 million. The corresponding increased shareholding percentage shall not in aggreg

4. APPENDICE

4.1 财务报表附注

截至 2020 年 9 月 30 日止

财务报表附注 (续) (人民币元)

Unit: Yuan Currency: RMB Type of audit: Unaudited

项目	2020 年 9 月 30 日	2019 年 12 月 31 日
流动资产:		
现金及银行存款	9,049,630,750.44	9,533,268,377.32
为交易目的持有的金融资产	1,016,412,863.26	456,650,637.52
应收票据	181,567,731.22	240,122,307.38
应收账款	4,983,425,346.63	4,367,599,412.33
应收保理	454,633,589.74	445,102,703.18
预付款项	594,704,488.24	415,675,156.23
其他应收款	490,781,542.13	404,921,541.85
包括: 应收利息	—	—
应收股利	13,634,552.90	39,844,668.93
存货	4,720,486,939.03	3,940,536,682.71
一年内到期的非流动资产	—	—
持有待售资产	—	—
其他流动资产	633,154,209.60	599,490,648.58
流动资产合计	22,124,797,460.29	20,403,367,467.10
非流动资产:		
债务投资	—	—
长期股权投资	22,247,141,819.69	20,929,776,138.99
其他权益工具投资	16,208,856.24	107,709,225.73
其他非流动金融资产	1,922,406,487.26	1,983,154,536.18
固定资产	7,539,634,611.07	7,410,365,672.57
在建工程	4,033,100,658.31	3,149,906,328.38
使用权资产	635,526,349.59	524,796,559.96
无形资产	8,586,461,086.63	7,915,974,071.42
开发支出	2,913,532,526.14	3,050,217,233.30
goodwill	8,895,931,115.68	9,013,990,317.19
长期递延资产	269,914,243.62	160,688,247.32
递延所得税资产	228,339,048.42	196,094,575.58
其他非流动资产	1,134,994,952.30	1,273,605,289.60
非流动资产合计	58,423,191,754.95	55,716,278,196.22
资产总计	80,547,989,215.24	76,119,645,663.32

C 6 Q 1 6 6 6 (Continued)
January - September 2020

I 6 Q 1	J - 2020	J - 2019	J 6 - 2020	J 6 - 2019
VI. Other comprehensive income, net of tax	54,775,747.28	-9,016,755.16	-100,190,979.89	34,958,479.93
Other comprehensive income attributable to the owners of the parent company, net of tax	24,685,826.76	7,142,372.12	-29,477,045.61	35,946,029.37
(i) Other comprehensive income not reclassified subsequently to profit or loss	14,961,357.53	144,152.81	87,712,955.49	-26,694,169.11
1. Changes as a result of remeasurement of net defined benefit plan liability or asset	—	—	—	—
2. Share of the other comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit or loss	16,990,050.34	—	85,922,577.29	—
3. Changes in fair value of other equity instrument investments	-2,028,692.81	144,152.81	1,790,378.20	-26,694,169.11
4. Changes in fair value of credit risk	—	—	—	—
(ii) Other comprehensive income reclassified subsequently to profit or loss	9,724,469.23	6,998,219.31	-117,190,001.10	62,640,198.48
1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss	-4,915,538.89	-27,514,726.87	23,042,853.48	-57,540,529.80
2. Difference in translation of foreign currency	14,640,008.12	34,512,946.18	-140,232,854.58	120,180,728.28
Other comprehensive income attributable to non-controlling interests, net of tax	30,089,920.52	-16,159,127.28	-70,713,934.28	-987,549.44
VII. Total comprehensive income	895,057,130.12	626,951,292.40	2,649,697,815.37	2,490,555,469.23
Total comprehensive income attributable to the owners of the parent company	788,956,224.49	554,726,673.16	2,449,503,506.39	2,099,650,177.36
Total comprehensive income attributable to non-controlling interests	106,100,905.63	72,224,619.24	200,194,308.98	390,905,291.87
VIII. Earnings per share:				
(i) Basic earnings per share (yuan/share)	0.30	0.22	0.97	0.81
(ii) Diluted earnings per share (yuan/share)	0.30	0.22	0.97	0.81

Legal Representative:

C 6 Q 1

Chief Financial Officer:

G 6 Q 1

Director of the Accounting Department:

C 6 Q 1

I6 r 6 : a n r a , : P : C , 6 - 6 r (Continued)
January - September 2020

I 6 r 6 : a n r a	J - : 2020	J - : 2019	J 6 - : 2020	J 6 - : 2019
V. Other comprehensive income, net of tax	10,589,675.45	-30,978,219.40	141,618,144.31	-48,270,519.29
(i) Other comprehensive income not reclassified subsequently to profit or loss	15,158,355.54	—	90,374,944.32	63,047.06
1. Changes as a result of remeasurement of net defined benefit plan liability or asset	—	—	—	—
2. Share of the other comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit or loss	16,990,050.34	—	85,922,577.29	—
3. Changes in fair value of other equity instrument investments	-1,831,694.80	—	4,452,367.03	63,047.06
4. Changes in fair value of credit risk	—	—	—	—
(ii) Other comprehensive income reclassified subsequently to profit or loss	-4,568,680.09	-30,978,219.40	51,243,199.99	-48,333,566.35
1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss	-4,568,680.09	-30,978,219.40	51,243,199.99	-48,333,566.35
VI. Total comprehensive income	485,371,001.50	304,043,422.11	1,171,123,090.61	1,017,414,580.33
VII. Earnings per share:				
(i) Basic earnings per share (yuan/share)	N/A	N/A	N/A	N/A
(ii) Diluted earnings per share (yuan/share)	N/A	N/A	N/A	N/A

Legal Representative:

C 6 r Q

Chief Financial Officer:

G 6 r a

Director of the Accounting Department:

C 6 r a

C, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100
 January - September 2020

I, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100	J, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100	J, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100
III. C, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100		
Cash received from capital contribution	80,093,059.40	2,975,118,171.03
Including: Cash received by subsidiaries from investments of non-controlling interests	80,093,059.40	2,975,118,171.03
Cash received from borrowings	12,581,404,305.72	8,596,315,233.75
Other cash received relating to financing activities	13,487,706.36	49,944,000.92
Sub-total of cash inflow generated from financing activities	12,674,985,071.48	11,621,377,405.70
Cash paid for debts settlement	8,918,752,402.99	6,760,545,407.43
Cash paid for the distribution of dividends, profits or interest	1,944,125,870.73	1,765,161,894.66
Including: Dividends and profits paid by subsidiaries to non-controlling interests	341,049,830.97	190,472,777.69
Other cash paid relating to financing activities	1,878,322,235.94	431,687,464.08
Sub-total of cash outflow generated from financing activities	12,741,200,509.66	8,957,394,766.17
Net cash flow generated from financing activities	-66,215,438.18	2,663,982,639.53
II. E, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100	-132,918,882.81	47,762,255.60
I. N, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100	-1,330,384,813.16	2,479,857,303.75
Plus: Opening balance of cash and cash equivalents	8,284,371,152.04	7,175,005,107.37
I. C, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100	6,953,986,338.88	9,654,862,411.12

Legal Representative:

C, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100

Chief Financial Officer:

G, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100

Director of the Accounting Department:

C, 6, r, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100

January – September 2020

Unit: Yuan Currency: RMB Type of audit: Unaudited

Unit: Yuan Currency: RMB Type of audit: Unaudited

I	J, 6 - 2020	J, 6 - 2019
I. Cash received from sale of goods and rendering of services	3,728,726.62	5,149,342.00
Refund of taxes and levies	—	—
Other cash received relating to operating activities	114,534,180.91	128,222,247.72
Sub-total of cash inflow generated from operating activities	118,262,907.53	133,371,589.72
Cash paid for purchasing goods and receiving services	—	—
Cash paid to and on behalf of employees	102,071,662.06	167,820,218.62
Cash paid for all types of taxes	37,560,868.24	28,739,071.01
Other cash paid relating to operating activities	56,982,249.98	24,225,610.78
Sub-total of cash outflow generated from operating activities	196,614,780.28	220,784,900.41
Net cash flow generated from operating activities	-78,351,872.75	-87,413,310.69
II. Cash received from disposal of investments	65,884,959.55	2,700,000.00
Cash received from returns on investments	672,593,975.62	559,642,923.39
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	281,500.00	119,450.00
Net cash received from disposal of subsidiaries and other operating segments	—	—
Other cash received relating to investing activities	—	—
Sub-total of cash inflow generated from investing activities	738,760,435.17	562,462,373.39
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	1,175,399.99	588,665.00
Cash paid for investments	131,105,177.61	201,134,710.66
Net cash paid for acquisition of subsidiaries and other operating segments	—	—
Other cash paid relating to investing activities	—	—
Sub-total of cash outflow generated from investing activities	132,280,577.60	201,723,375.66
Net cash flow generated from investing activities	606,479,857.57	360,738,997.73

Cash Flow Statement (Continued)
 January – September 2020

I	J, 6 - 2020	J, 6 - 2019
III. Cash flow from financing activities:		
Cash received from capital contribution	—	—
Cash received from borrowings	6,227,808,000.00	5,568,766,507.00
Other cash received relating to financing activities	8,374,711,260.81	6,954,926,338.94
Sub-total of cash inflow generated from financing activities	14,602,519,260.81	12,523,692,845.94
Cash paid for debts settlement	4,917,282,400.00	3,883,257,655.50
Cash paid for the distribution of dividends, profits or interest	1,359,956,597.26	1,179,657,342.95
Other cash paid relating to financing activities	9,281,176,261.13	7,370,819,258.74
Sub-total of cash outflow generated from financing activities	15,558,415,258.39	12,433,734,257.19
Net cash flow generated from financing activities	-955,895,997.58	89,958,588.75
IV. Effect of exchange rate changes on cash and cash equivalents	-700,928.75	-26,475.30
V. Net change in cash and cash equivalents	-428,468,941.51	363,257,800.49
Plus: Opening balance of cash and cash equivalents	515,360,096.42	455,240,544.03

